profile

Biogen Inc

short

$BIIB  Bullshit they halted you guys saving the shorts !

$AVXL Reality Check: Anavex has the greatest AD and PD data to ever exist, with 100% safety, yet shorts are acting as if somebody died.

chart

$BIIB Chart isn&#39;t looking promising for the stock.

It also doesn&#39;t help that there is still that lingering gap in the chart that needs to be filled. ..

It also doesn&#39;t help that there is still that lingering gap in the chart that needs to be filled

pump-and-dump

$BIIB about time this pump bled out. Jeez

$BIIB   Calling complete BULLSHIT on this pump! !

board

patient

CURING LEUKEMIA isn&#39;t a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

One drug, Recorlev, just rolling out, best in class drug for advanced Cushings being received exceptionally well by doctors and likely thousands of patients will switch at an annual Rx of $250k-350k, will provide hundreds of millions of new revenue.

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

$AVXL had patients that actually improved (reversed cognitive decline) vs just slowing it down.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

This may result in a more favorable risk-benefit analysis for treatment.

$BIVI drug is very safe and well tolerated with zero adverse events in over 400 patients.

$AVXL $BIIB  many patients on Blarcamesine Improved from when they began taking it!

approval

Biogen $BIIB gains as analysts reflect positively on Leqembi&#39;s approval, pricing https://www.streetinsider.com/Analyst+Comments/Biogen+%28BIIB%29+gains+as+analysts+reflect+positively+on+Leqembis+approval%2C+pricing/21047807.html

$BIIB nice how quickly they turned around and filed for full approval right after receiving AA.

Well it was bound for an approval because the bar is low and aggregate economic benefit would far outweigh the aggregate economic burden from funerals cost

Bullish for $AVXL $BIVI

no more speculation, now it&#39;s real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!

$AVXL More excitement here than with $BIIB Approval and no big price increase.

$BIIB wow unhalted, the stock up 1$ after approval, nice 🤣

$BIIB so drug approval is good for a stock.. 
good to know

$BIIB Approval with Warnings--This is great for Bulls: The prescribing information for Leqembi includes a warning for amyloid-related imaging abnormalities (ARIA), which are known to occur with antibodies of this class.

Re listening to calls and noticed Stacy is always clear &amp; confident in explaining mechanism of action

This is amongst the best returns in the industry. https://www.chartmill.com/stock/quote/BIIB/fundamental-analysis?key=899cf62b-e33c-45fc-88bd-db1b4449c69b&amp;utm_source=stocktwits&amp;utm_medium=FA&amp;utm_content=BIIB&amp;utm_campaign=social_tracking

industry

Emed will have a huge market for their devices and imo will revolutionize the pain management industry.

$BIIB the good news is the Bio industry is recession proof

HeartBeam Inc

If you ever wanted to know what a fake pumper profile looks like it’s this guy.

I wonder how many other fake temp profiles this person has used on other pumps he’s tried orchestrating.

$BEAT Be careful getting caught in this pump.

application

The answer to the question about the delay of FDA approval was absolutely pathetic (&quot;We had forgotten that there would be a holiday&quot;)!

The promise of a FDA decision left this stock to shit.

Due to the delay and the problems with the FDA.

You do all that is required by a Government Agency (FDA)  and now you are Basically dead in the water until they make an announcement.

loss

$BEAT closed trade @$4.40 for a -3% loss.

but the got a loss (I don’t like shorting) 😂😂💪

He missed the boat and is now deep into losses.

company

But these people (who asked the questions) were all really well acquainted with the company and the products, and they covered absolutely every important aspect.

Such a good company too.. ..what a waste.

Low float, now company has been doing better than ever.

With only one prospectus/registration, it gives company flexibility to raise capital based on need and market conditions for 3 years without having to again go through whole filing process, that includes time and expense.

Once approved, company will soon apply for FDA approval of the primary product that has so many excited about this company.

$BEAT Nice to see a company with a CEO that actually cares  enough about the Shareholders to make an End of the year Update.

This is what people are most excited about when looking at this companies future.

IMO, at current share price, one or both companies will be huge winners for investors.

potential

I think this company holds a lot of potential.

$BEAT $BLUE $CLNV $PRVB $VKTX 

Every single one has now offered the potential 10-50%+ gains since this post

$BEAT Peter J. Fitzgerald, MD, PhD seems like an incredibly impressive person to have join this micro cap company, and adds considerable credibility to the potential for their products.

Huge potential market We saw $beat run over 200% from my first mention a month or so back

Leadership are pros and the setup is excellent given the recent theme of runners we’ve seen.

📈 Scan as of now “TODAY’S GAPPERS WITH MORE POTENTIAL” 10/06/2022 
 
$BEAT #1 on the scanner with 21.7 million shares and up by 20.3% , $PRVB #2 with 6.8 million shares and up by 23.4% 
  
Good luck everyone 🍀

technology

Heartbeat technology is far ahead of its competition!

This technology is truly game changing and when approved production will respond quickly.

$beat has technology and products that may save many, many lives.

but I do feel the area of medical technology and healthcare provide for good investment opportunity.

Currently I am very Bullish on $ivda and $beat that I believe both have Technology and or AI that could be disruptive and hugely profitable to investors.

$BEAT technology is great at Diagnosing Heart Attack during hump day.

Here is a company that will save huge amount of lives with new/updated technology and has a market cap of 32 million!!!!!

&quot;We were pleased by the progress our team has made over the past quarter, highlighted by our decision to expand the addressable patient population for our HeartBeam AIMI platform technology by including unstable angina as a diagnosis for analysis.

$BEAT couple of people got a nice dip for the new year.

$ILAG  
Going to be accumulating dips ; I feel like this has a lot more room to go.

$BEAT DIP BEFORE 💫💫💫

MARK THAT BABY

smart money was accumulating on the dip and that accumulation is continuing.

$BEAT so thankful I sold at $5 and the nice re-entry dip!! !

G1 Therapeutics Inc

launch

The friction of launching their own sales force is no longer an excuse - the biggest concern is that myelosuppresion might not be on front of doctors minds.

revenue

$GTHX ridiculous 
27% drop on flat revenue is not acceptable

sale

$GTHX disappointed with sales 
Below par WTF sales team is doing ?

joke

price

There are too many instances of apparent stock manipulations and stupid mgmt decisions (unnecessary dilutions, poorly timed PR) that keep destroying share price and making me question whether having a good pharmacy product is good enough.

data

The future data readouts seems positive as clinical team understands why would be positive as compared to CRC.

$GTHX hoping for double from here on positive CRC data!! !

$GTHX It seems almost every trading day i see a small cap biotech that is up 75-100% on positive data and news.

Jack danced around the fact that the data is positive. 6.

Still ok data- a halfway decent hors d’oeuvre, in preparation for the main course of CRC

$SIMO holding for 3-5 months for buyout approval: 60% upside with 3% annual dividends

$TSM lovely uptrend and holding till next year

$CRIS waiting for data on monday (ash/webcast)

$GTHX Like the offering and opportunity for bounce

$GTHX JPMs note on G1’s data read today - more upbeat than usual.

A lot of good data  can come from now into 23.

news

$GTHX add to all those catalysts potential partnership news

$GTHX This is great news for G1 Therapeutics.

$GTHX The good news for this company keeps coming in study after study.

$GTHX great news today albeit small patient pool.

$GTHX Come on, let&#39;s go back: If you&#39;ve noticed, the stock hasn&#39;t dropped below 6.30 and this is good news.

conference

$GTHX This gem crossed my path when looking through some of the health conference information.

$ESPR Esperion Hosting Virtual Research &amp; Development Day 
 
($BCRX and $GTHX R&amp;D days were great,

increase

The adressable market will grow from 20k to 47k patients: 137% increase

2.

Top Stocks matching your search for "options profile"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

BIIB

Biogen Inc

-8.49%

$285.45 - $261.22

Nov, 14, 2022

BEAT

HeartBeam Inc

-35.90%

$3.90 - $2.50

Sep, 29, 2022

GTHX

G1 Therapeutics Inc

-59.51%

$7.78 - $3.15

Dec, 9, 2022

BIIB

Biogen Inc

-8.49%

$285.45 - $261.22

Nov, 14, 2022

BEAT

HeartBeam Inc

-35.90%

$3.90 - $2.50

Sep, 29, 2022

GTHX

G1 Therapeutics Inc

-59.51%

$7.78 - $3.15

Dec, 9, 2022